High Expression of Both Resistin and Fascin‐1 Predicts a Poor Prognosis in Patients with Colorectal Cancer

BioMed Research International

Huang

et al. 2020

Self Cite

It is unclear whether the methyltransferase-like 14 (METTL14) protein promotes or suppresses cancer growth. We examined the association between METTL14 expression, cancer progression, and patient prognosis in a total of 398 breast cancer tissue specimens. Significantly fewer cancer tissue specimens compared with normal breast tissue expressed high levels of METTL14 (52.8% vs. 75.0%). METTL14 expression was negatively associated with tumor grade and positively associated with patient age, estrogen, and progesterone receptor status. High METTL14 expression was more common in luminal A and luminal B tissue (75.9% and 60.8%, respectively), compared with human epidermal growth factor receptor 2- (HER2-) enriched and triple-negative breast cancer (TNBC) samples (38.2% and 18.6%, respectively). In multiple logistic regression analysis, independent predictors of METTL14 expression in breast cancer included higher tumor grade ( odds ratio OR = 0.494 , 95% confidence interval (CI): 0.289–0.844; P = 0.010 ), TNBC subtype ( OR = 0.109 , 95% CI: 0.054–0.222; P < 0.001 ), and HER2-enriched subtype ( OR = 0.298 , 95% CI: 0.156–0.567; P < 0.001 ). No clear relationship was observed between patient prognosis and METTL14 expression. It appears that downregulated METTL14 expression in breast cancer is associated with tumor grade and molecular classification.

Section: Methodsmentioning

confidence: 99%

“…We followed the methods of Wang et al [ 29 ]. In brief, each patient was followed up postoperatively by telephone call and thereafter at 6 monthly hospital appointments; follow-up was discontinued in the event of the patient's death.…”

Section: Methodsmentioning

confidence: 99%

Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification

Dong

BioMed Research International

Huang

et al. 2020

Self Cite

“…Wang et al 2020. [ 22 ] In brief, the Quick-Ray UT-06 (Unitma Co., Ltd., Seoul, Korea) tissue microarray system and the Quick-Ray premade recipient block (UB-06) wax model were used to prepare tissue specimens (1 mm in diameter). Two representative sites from each breast cancer tissue sample were selected for sampling.…”

Section: Methodsmentioning

confidence: 99%

p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status

Wang¹,

Tang

et al. 2021

Medicine

Self Cite

Although some studies have reported the expression and clinical significance of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) in breast cancer tissues, it is still controversial whether p-STAT3 play a role in promoting or suppressing cancer. Here, we used immunohistochemistry analysis to explore expression of p-STAT3 in 407 cases of breast cancer, and analyzed the relationship between p-STAT3 expression and the clinicopathological characteristics and prognosis of breast cancer patients. Positive p-STAT3 expression was seen in 112 cases (27.5%) of breast cancer. p-STAT3 expression was negatively correlated with tumor size, tumor stage and human epidermal growth factor receptor 2 (HER2) status, and the positive rate of p-STAT3 was lowest in HER2-enriched subtype breast cancer (15.3%), while other subtypes were luminal B (23.0%), luminal A (30.2%), and triple-negative breast cancer (TNBC) (37.5%). Logistic regression model multivariate analysis showed that the independent correlation factor of p-STAT3 expression in breast cancer was tumor size (OR = 0.187, 95% CI = 0.042–0.839, P = .029) and HER2 status (OR = 0.392, 95% CI = 0.216–0.710, P = .002). In this study, no clear relationship was observed between patients’ prognosis and expression of p-STAT3. Therefore, we suggest that p-STAT3 expression in breast cancer is negatively correlated with tumor size and HER2 status, but appears to have no effect on survival.

“…IHC Analysis. We followed the methods of Wang et al [18]. The primary antibodies consisted of anti-resistin mouse monoclonal antibody (clone C-10, diluted at 1 : 25; Santa Cruz Biotechnology, Santa Cruz, USA), anti-EGFR rabbit polyclonal antibody (clone 1005, diluted at 1 : 100; Santa Cruz Biotechnology), anti-ERK1/2 rabbit monoclonal antibody (clone EPR18444, diluted at 1 : 1000; Abcam, Cambridge, England), ready-to-use anti-ER rabbit monoclonal antibody (clone SP1, Dako), ready-to-use anti-PR mouse monoclonal antibody (clone PgR636, Dako), HercepTest (Dako), and ready-to-use anti-Ki-67 mouse monoclonal antibody (clone MIB-1, Dako).…”

Section: Methodsmentioning

confidence: 99%

“…The entire section was scanned and scored independently by 2 pathologists. Resistin and EGFR expression staining intensity was scored on a 4-point scale from 0 (negative) to 1 (weak), 2 (moderate), or 3 (strong) [18]. A case was recorded as resistin-positive if the cytoplasmic staining intensity of positive invasive cancer cells was 2 or 3; 3 was deemed strongly positive [8].…”

Section: Methodsmentioning

confidence: 99%

Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer

Zeng

Tang

BioMed Research International

et al. 2020

Self Cite

Elevated levels of resistin and epidermal growth factor receptor (EGFR) facilitate the development of breast cancer, although there are no reports of any correlation between these proteins. This study analyzed 392 human breast cancer tissue specimens and 42 samples of adjacent normal tissue. Rates of positive and strongly positive resistin expression were significantly higher in breast cancer tissue than in the adjacent nontumor tissue (83.2% vs. 23.8% and 20.9% vs. 0.0%, respectively; P < 0.001 for both comparisons). Positive resistin expression was significantly associated with tumor size, grade, stage, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, and molecular classification; strongly positive resistin expression was associated with tumor grade, ER, PR, HER2 status, and molecular classification. Significantly positive correlations were observed between positive and strongly positive resistin expression and corresponding levels of EGFR expression. Relapse-free and overall survival was worse for patients with high levels of both proteins than for those with high levels of only one protein or normal levels of both proteins. Our evidence suggests that combined high levels of resistin and EGFR expression correlate with survival in patients with breast cancer.